Proton Re-irradiation for Head and Neck Cancer Recurrence

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational study follows adults with recurrent head and neck cancer who are slated to receive proton therapy as a second course of radiation. Researchers will monitor safety, tumor control, survival, and quality of life to understand how well proton therapy works in re-irradiation scenarios. The study aims to identify which patients may benefit most and how treatment planning can be optimized to minimize harm to surrounding tissues. No experimental treatments are given; the study observes outcomes from standard clinical care. Participation requires informed consent and is conducted at a single center in Italy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥ 18 years old
* ECOG 0-2
* Pathologically and or radiologically confirmed head and neck cancer recurrence
* Indication for proton therapy
* Written informed consent for REPRO-HN according to applicable legal and ethical requirements by the end of radiotherapy treatment

Exclusion Criteria:

* Age \< 18 years old
* ECOG\>3
* Life expectancy \< 3 months
* Inability to provide informed consent

Where it's running

• IRCCS Humanitas Research Hospital
  Rozzano, Milano, Italy Recruiting

Study contacts

• Principal investigator: Maria Ausilia Teriaca, MD, radiation oncologist — Humanitas Research Hospital IRCCS, Rozzano-Milan
• Study coordinator: Maria Ausilia Teriaca, MD, radiation oncologist
• Email: maria.ausilia.teriaca@cancercenter.humanitas.it
• Phone: +39 0282247461

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Proton Re-irradiation for Recurrent or Second Primary Head and Neck Cancer

  This study tests proton radiotherapy to see if it can control head and neck cancer that has come back or appeared again in the same area, while trying to limit side effects.

  Recruiting Oslo University Hospital · Bergen and 3 other locations · NCT07922967

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

• BupiZenge vs Lidocaine for mouth pain from oral mucositis in head and neck cancer

  A phase 3 trial tests whether the BupiZenge lozenge provides better pain relief than lidocaine for mouth sores caused by radiation in head and neck cancer patients.

  Recruiting at 9 sites Phase 3 OncoZenge AB · Copenhagen and 10 other locations · NCT07672236

• Intratumoral EDS01 plus toripalimab for recurrent or metastatic head and neck cancer

  This phase 1 study tests whether directly injecting a gene‑therapy endostatin product (EDS01) into a tumor, together with the PD-1 inhibitor toripalimab, is safe and shows early signs of activity in adults with recurrent or metastatic head and neck cancer after platinum therapy.

  Recruiting Phase 1 West China Hospital · Chengdu, China · NCT07625423

• Specialist nurse-led perioperative nursing care for head and neck cancer surgery

  A multidisciplinary team of specialist nurses tests whether a nurse-led perioperative care plan improves recovery for people having head and neck cancer surgery.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07622381

• Nimotuzumab plus Immunotherapy and Chemotherapy before surgery for locally advanced head and neck cancer

  This phase 2 trial tests whether adding nimotuzumab to immunotherapy and chemotherapy before surgery helps people with locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07601737

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.